Definitive Contract HHSN272201600012C

This is a federal contract award to Glaxosmithkline, LLC, a pharmaceutical company, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $1,937,251.00, is for the design and development of preventative HIV vaccines. The contract has an ultimate completion date of April 30, 2018 and was awarded on October 31, 2015. The contract is a definitive contract with a cost no fee pricing type and does not have a set-aside designation. Glaxosmithkline, LLC has provided a range of pharmaceutical products and services to various U.S. government agencies through federal contracts and grants, including vaccines, antiviral medications, and drug development support.